ENSCW Ensysce Biosciences, Inc.
Price Chart
Executive Summary
Ensysce Biosciences filed an S-3 registration statement to register 1,300,000 shares of common stock for resale by selling securityholders — 1,280,000 shares issuable to Galephar Pharmaceutical Research under a manufacturing agreement and 20,000 shares to a consultant. The company will not receive any proceeds from these resales. The filing comes as Ensysce faces a going-concern warning, Nasdaq delisting risk (both stockholders' equity and bid price non-compliance), and cash runway only into late Q2 2026, making this a routine resale registration that does not raise new capital but highlights the company's distressed financial position.
Actionable Insight
This S-3 is a resale registration that does not raise capital for Ensysce, but the potential for up to 1.3M shares to hit the market adds overhang to an already distressed stock. The company's cash runway into late Q2 2026 and dual Nasdaq delisting risks (equity and bid price) are the dominant concerns. Monitor for any Nasdaq compliance plan submission (due by July 6, 2026) and for any further draws on the $16M Securities Purchase Agreement facility, which would be highly dilutive given the current $0.262 stock price.
Key Facts
- Registers 1,300,000 shares for resale by selling securityholders (Galephar: 1,280,000 shares; Hector Feliciano: 20,000 shares)
- Company receives no proceeds from the resale of these shares
- Auditor's report includes going-concern uncertainty; cash on hand sufficient only into late Q2 2026
- Nasdaq notified Ensysce on May 21, 2026 of non-compliance with $2.5M stockholders' equity requirement (Rule 5550(b)(1))
- Nasdaq also notified on Feb 25, 2026 of bid price non-compliance (below $1.00 for 30+ consecutive business days)
- Common stock closed at $0.262 per share on June 2, 2026; warrants (ENSCW) closed at $0.0062
- S-3 is an additional registration beyond the April 2025 registration statement due to stock price decline and milestone achievements
- Securities Purchase Agreement requires Ensysce to offer up to an additional $16M of securities to an investor over two years
Financial Impact
No new capital raised; registration covers up to 1,300,000 shares at a reference price of $0.2977 per share (max aggregate offering price $387,010). Potential overhang from resale of up to 8.5% of outstanding shares (15,365,530 shares outstanding as of June 2, 2026).
Risk Factors
- Nasdaq delisting risk from both stockholders' equity and bid price non-compliance
- Going-concern uncertainty with cash only through late Q2 2026
- Potential overhang from resale of 1.3M registered shares (8.5% of outstanding)
- Highly dilutive future draws on the $16M Securities Purchase Agreement facility at current depressed stock prices
- No new capital raised from this filing to address liquidity needs
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-027289 |
| Exhibit: ex107.htm | 0001493152-26-027289 |
| Exhibit: ex5.htm | 0001493152-26-027289 |
| Exhibit: ex23-2.htm | 0001493152-26-027289 |
| Document: 0001493152-26-027289-index-headers.html | 0001493152-26-027289 |
| Document: 0001493152-26-027289-index.html | 0001493152-26-027289 |
| Document: 0001493152-26-027289.txt | 0001493152-26-027289 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
S-3
| — | awaiting T+20 | — | — |
|
May 22, 2026
14d ago
|
8-K
| — | awaiting T+20 | — | — |
|
May 15, 2026
21d ago
|
8-K
| — | awaiting T+20 | — | — |
|
Apr 3, 2026
9w ago
|
8-K
| — | awaiting T+20 | — | — |
|
Mar 30, 2026
9w ago
|
8-K
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access